Association of Apolipoprotein B-48 Level and Large arterY Atherosclerotic iSchemic Stroke(ABYSS)
NCT ID: NCT01233986
Last Updated: 2011-10-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
112 participants
OBSERVATIONAL
2010-05-31
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case group - Large artery atherosclerosis
No interventions assigned to this group
Control group-Small vessel occlusion
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age over 20 years
* Patients with symptomatic stenosis in the eligible vessels(the middle cerebral artery, anterior cerebral artery, or internal carotid artery) as assessed by MRA or CTA corresponding to the acute ischemic stroke
* Patients without the occlusion of corresponding artery by MRA or CTA
* The fasting and postprandial serum Apo B-48 level can be assessed within 72 hours after the symptom onset of ischemic stroke
Small vessel occlusive ischemic stroke group (SVO group)
* Age over 20 years
* Patients with acute ischemic stroke of basal ganglia, internal capsule, or corona radiata
* Patients without both symptomatic and asymptomatic arterial occlusion or stenosis by MRA or CTA
* Patients without a history of systemic atherosclerosis(for example, acute myocardial infarction, angina, peripheral arterial disease, aortic aneurysm)
* The fasting and postprandial serum Apo B-48 level can be assessed within 72 hours after the symptom onset of ischemic stroke
Exclusion Criteria
* Patients treated with lipid lowering agents or steroid within the previous 30 dsys
* Patients with severe liver disease (AST \>100 or ALT \>100) at the time of randomization
* Patients with endocrine disease except diabetes mellitus at the time of randomization (for example, thyroid disease, adrenal disease)
* Patients with severe renal disease (serum creatinine \>2.0mg/dl)at the time of randomization
* chronic alcoholics or drug user
* Patients with infection at the time of randomization
* Patients, in the opinion of the investigator, unlikely to comply with the clinical study or unsuitable for the any other disease or reason
* Informed consent has not been obtained
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hallym University Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Byung-Chul Lee, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Hallym University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hallym University Sacred Heart Hospital
Anyang, Anyang, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ABYSS
Identifier Type: -
Identifier Source: org_study_id